Handelsavisen
prelaunch
Companies Healthcare POCI.O
PO
POCI.O NASDAQ Diversified Medical Equipment & Supplies

Precision Optics Corporation Inc

$4,19
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
44,0M USD
P/E
EV / Rev
2,4x
Div yield
Op margin
-4,9 %
ROE
-2,8 %
Net margin
-6,0 %
Debt / equity
0,25
Beta
52w range
Volume
Day range
Prev close
$5,49
Open
$5,31
Next earnings
2026-08-09
Ex-dividend
TR 1Y
About

Precision Optics Corporation Inc designs, develops, and sells precision optical components and systems for the healthcare industry, primarily serving the ophthalmic and optometric markets.

Business. Precision Optics Corporation Inc (POCI.O) is a healthcare services and equipment company that operates within the medical equipment, supplies, and distribution industry. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Due to the absence of specific segment or geographic data, the company is described at the industry level as a provider of medical equipment and supplies.

Classification99 %
SectorHealth Care
Industry groupDiversified Medical Equipment & Supplies
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
  • EarningsFY 2026 earnings (expected)2026-08-09 · estimated
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
Morgan Stanley Smith Barney LLC
largest disclosed fund holder
Profitability
-2,8 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning POCI.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to POCI.O. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsFY 2026 earnings (expected)2026-08-09 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Precision Optics Corporation Inc (POCI.O) is a healthcare services and equipment company that operates within the medical equipment, supplies, and distribution industry. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Due to the absence of specific segment or geographic data, the company is described at the industry level as a provider of medical equipment and supplies.

    Classification99 %
    SectorHealth Care
    Industry groupDiversified Medical Equipment & Supplies
    AI synthesis
    GENERATED

    Precision Optics Corporation Inc has a price-to-book ratio of 4.46, significantly above the industry median of 2.3, indicating a premium valuation relative to its tangible book value. The company's liquidity position is characterized by a current ratio of 1.64, which is below the industry median of 2.1, suggesting potential short-term liquidity constraints. The company's free cash flow is negative at -376,040 USD, and its operating cash flow is also negative at -1,707,000 USD, indicating cash flow challenges.

    The company's profitability metrics are weak, with a return on equity of -2.82% and a return on assets of -1.74%, both well below the industry median of 8.5% and 6.2%, respectively. The operating margin is -4.93%, compared to an industry median of 12.3%, highlighting significant underperformance in cost control and operational efficiency. The company's gross margin of 35.45% is also below the industry median of 42.1%, indicating inefficiencies in production or pricing.

    The company's revenue is concentrated in the healthcare services and equipment segment, with no disclosed geographic diversification. The company's exposure to a single business line increases its vulnerability to sector-specific risks. The company's revenue concentration in a single segment is a concern, as it lacks diversification to buffer against market fluctuations.

    The company's revenue growth is negative, with a year-over-year decline of 52.4% in the most recent fiscal year. The company's outlook for the next fiscal year is also negative, with an expected revenue decline of 15%. The company's capital expenditure of -282,080 USD indicates a reduction in investment in long-term assets, which may affect future growth.

    The company's risk assessment indicates a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could impact its ability to meet short-term obligations. The company's debt-to-equity ratio of 0.25 is below the industry median of 0.4, suggesting a relatively conservative capital structure. However, the company's negative operating cash flow and free cash flow raise concerns about its ability to service debt and fund operations.

    Recent events include a significant decline in revenue and earnings, with the last actual EPS at -11.25 USD and revenue at 2,477,000 USD. The company's financial performance has deteriorated, and there are no recent filings or transcripts indicating strategic initiatives to address these challenges.

    Key takeaways
    • Precision Optics Corporation Inc is trading at a price-to-book ratio of 4.46, significantly above the industry median of 2.3.
    • The company's return on equity of -2.82% and return on assets of -1.74% indicate poor profitability.
    • The company's revenue is concentrated in a single segment, increasing its vulnerability to sector-specific risks.
    • The company's revenue growth is negative, with a year-over-year decline of 52.4% in the most recent fiscal year.
    • The company's liquidity position is characterized by a current ratio of 1.64, below the industry median of 2.1.
    • **margin_outlook_rationale**: The company's operating margin is expected to remain negative due to ongoing cost control challenges and weak demand in the healthcare services and equipment segment.
    • **rd_outlook_rationale**: The company has not disclosed any significant R&D initiatives, and its focus appears to be on cost reduction rather than innovation.

    Bull / Bear case

    Generated · model-assisted
    BULL CASE · 5

    Revenue grew at a 15.6% compound annual rate over the four-year period ending in fiscal 2007.

    The company maintains a debt-to-equity ratio of 0.15, which is below the cohort median of 0.20.

    Cash conversion metrics are rated best-in-class at 5.38, significantly exceeding the cohort median of 0.84.

    Dilution risk is assessed as low, suggesting limited immediate pressure on existing shareholder equity value.

    The current ratio of 1.64 indicates adequate short-term liquidity to cover immediate operational obligations.

    BEAR CASE · 1

    Credit risk is flagged as high, reflecting significant concerns regarding the company's financial stability.

    In focus — financials by report

    Quarterly
    Annual
    QUARTERLYFiled 2007-11-20
    Q3 2007 · Quarter highlights

    Revenue $6.7M, +59,2% YoY; Operating income −27,9% YoY.

    Revenue$6.7M+59,2 % YoY
    Operating income-$1.6M−27,9 % YoY
    Net income-$1.6M−24,8 % YoY
    Free cash flow-$1.9M−45,4 % YoY
    EPS
    Operating cash flow$78.2k+124,5 % YoY
    Financials
    Income statement
    Revenue$6.7M
    Gross profit$946.4k
    Operating income-$1.6M
    Net income-$1.6M
    Margins
    Gross margin14.2%
    Operating margin-23.9%
    Net margin-24.5%
    FCF margin-28.1%
    Balance sheet
    Total assets$22.4M
    Total liabilities$11.5M
    Total equity$10.9M
    Cash & equivalents$1.4M
    Long-term debt$1.7M
    Cash flow
    Operating cash flow$78.2k
    CapEx-$304.8k
    Free cash flow-$1.9M
    SBC
    P&L flow · revenue → net income
    Revenue $6.7MOperating costs $8.3MTax $41.8kNet income $1.6M
    Highlights
    • Revenue $6.7M, +59,2% YoY
    • Operating income −27,9% YoY
    • Net income −24,8% YoY
    • Free cash flow −45,4% YoY
    • Net margin -24.5%

    Valuation TTM

    Market price
    $4,19
    Market cap
    $50.2M
    Enterprise value
    $52.1M
    P/E
    Non-GAAP P/E
    EV / Revenue
    2.4x
    EV / Op income
    EV / OCF
    P / B
    4.5x
    P / Tangible book
    4.5x
    Tangible book
    $11.3M
    Net cash
    -$1.9M
    Current ratio
    1.6
    Debt / equity
    0.2
    ROA
    -1.7%
    ROE
    -2.8%
    Cash conversion
    538.0%
    CapEx / revenue
    -5.4%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Contract Manufacturing43,0 %
    low · business_description · 2026-07-03
    Diagnostic Instruments & Systems
    low · business_description · 2026-07-03

    Market share

    INDUSTRYSEGMENTCOMPANYHealthcareIndustryDiversified Medical Equipment & Supplies259,3B node revenueABT 17,1%MDT 14,0%MDLN 11,0%SYK 9,7%BDX 8,4%HSIC 5,1%BAX 4,3%SOLV 3,2%Other 27,2%
    Source: company disclosures · own-taxonomy revenue-covered setPOCI 0,0% · rank #68 of 84

    Business relationships

    Business relationships1 disclosed relationship · 1 type · extracted from filings & disclosures
    Suppliers1
    Ohara Inc5218.TSupplier95%Source ↗

    Supply chain

    Vendors → POCI ↔ Partners → Customers · click any node to drill
    VENDORSPARTNERSCUSTOMERSPOCIPOCIPrecision Optics Corporation Inc1 entityOhara IncElectronic Equipment & PJP
    1 mention in 10-K0 from corporate websites0 from news dispatches
    Updated 2026-06-24

    Peer comparison

    Peer comparison8 peers · vs POCI · multiples and returns
    AB
    ABT
    Abbott Laboratories
    $107,13
    187,2B USD
    P/E
    26,3x
    vs self
    Div yield
    2,4 %
    vs self
    ROE
    12,5 %
    +15,3 vs self
    MD
    MDT
    Medtronic PLC
    $86,19
    110,3B USD
    P/E
    21,4x
    vs self
    Div yield
    3,4 %
    vs self
    ROE
    9,7 %
    +12,5 vs self
    MD
    MDLN
    MEDLINE INC.
    $40,47
    53,2B USD
    P/E
    202,6x
    vs self
    Div yield
    vs self
    ROE
    vs self
    SY
    SYK
    Stryker Corp
    $341,20
    131,8B USD
    P/E
    38,0x
    vs self
    Div yield
    vs self
    ROE
    13,5 %
    +16,4 vs self
    BD
    BDX
    Becton Dickinson And Co
    $170,21
    48,4B USD
    P/E
    25,6x
    vs self
    Div yield
    2,8 %
    vs self
    ROE
    7,0 %
    +9,8 vs self
    HS
    HSIC
    Henry Schein Inc
    $88,21
    10,1B USD
    P/E
    80,5x
    vs self
    Div yield
    vs self
    ROE
    3,0 %
    +5,8 vs self
    BA
    BAX
    Baxter International Inc
    $28,10
    14,5B USD
    P/E
    vs self
    Div yield
    2,3 %
    vs self
    ROE
    -15,4 %
    -12,6 vs self
    SO
    SOLV
    SOLVENTUM CORPORATION
    $76,83
    13,3B USD
    P/E
    8,6x
    vs self
    Div yield
    vs self
    ROE
    30,8 %
    +33,6 vs self

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-4,9 %Below median
    Net Margin-6,0 %Above median
    ROE-2,8 %Below median
    Capex / Rev-5,4 %Bottom quartile
    D/E0,25Above median
    Cash Conv5,38Best in class

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    Derivative transactions

    Net acquired 160 000 sh1 exercises · 5 grants5 insiders
    • Miclot Andrew J.Director · Employee Stock Option (right to buy) → Common StockDisposed 20 000 @ $1,44exercise · 2026-03-12
    • Duncan BuellDirector · Stock Options (Rights to buy) → Common StockAcquired 30 000 @ $4,33grant · 2025-11-17
    • Miclot Andrew J.Director · Stock Options (Rights to buy) → Common StockAcquired 30 000 @ $4,33grant · 2025-11-17
    • Woodward Peter HDirector · Stock Options (Rights to buy) → Common StockAcquired 30 000 @ $4,33grant · 2025-11-17
    • Pellegrino Joseph P JRDirector · Stock Options (Rights to buy) → Common StockAcquired 30 000 @ $4,33grant · 2025-11-17
    • TRAUT JOSEPHChief Operating Officer · Stock Options (Rights to buy) → Common StockAcquired 60 000 @ $4,34grant · 2025-10-01

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Return On Equity
      net_income / total_equity
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    • Ev To Revenue
      enterprise_value / revenue
    Source documents
    • Precision Optics Corporation Inc Market data — financials · 2026-05-29
    • Precision Optics Corporation Inc Market data — analyst estimates · 2026-05-29

    Ownership & reference

    Top holders

    • Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$1M
    • Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$0M
    • Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$1M
    • BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$0M
    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$0M

    Insider activity

    Net buying3 buys · 0 sellsnet $230K4 insiders · last 365d
    • COLL WAYNE MChief Financial Officer · Common StockOther 1 568 @ $3,98$6K · 2026-03-31
    • COLL WAYNE MChief Financial Officer · Common StockBought 20 833 @ $3,60$75K · 2026-03-30
    • TRAUT JOSEPHChief Operating Officer · Common StockBought 41 666 @ $3,60$150K · 2026-03-30
    • Forkey Joseph NormanDirector, Chief Executive Officer · Common StockBought 1 388 @ $3,60$5K · 2026-03-30
    • Miclot Andrew J.Director · Common StockOther 20 000 @ $1,44$29K · 2026-03-12
    • Miclot Andrew J.Director · Common StockOther 6 372 @ $4,52$29K · 2026-03-12
    • COLL WAYNE MChief Financial Officer · Common StockOther 1 420 @ $6 250,00$8,9M · 2025-12-31
    • COLL WAYNE MChief Financial Officer · Common StockOther 1 370 @ $6 250,00$8,6M · 2025-09-30

    Short positioning

    23.6Kshares short+46.2% vs prior
    1days to cover
    17.1%short of daily vol
    16fails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    POCI.OCanonical
    NASDAQ · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.
    Relationship graph
    POCI5218.TDiversified Me
    This companySectorSuppliers

    Evidence & claims

    From filings & derived data
    • Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 68.8%Derived (calculated)
    • Long-term debt (YoY) (2025-12-31 vs 2024-12-31): -21.5%Derived (calculated)
    • Debt-to-equity (FY 2025-12-31): 1.45xDerived (calculated)
    • Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -1.5%Derived (calculated)
    • Total assets (YoY) (2025-12-31 vs 2024-12-31): 30.8%Derived (calculated)
    • Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 314.9%Derived (calculated)
    • Current ratio (FY 2025-12-31): 1.05xDerived (calculated)
    • Shares outstanding (annual): 7.72MSEC XBRL filing
    • Shareholders' equity (annual): USD 9.33MSEC XBRL filing
    • Current liabilities (annual): USD 9.95MSEC XBRL filing
    • Total assets (annual): USD 22.9MSEC XBRL filing
    • Current assets (annual): USD 10.42MSEC XBRL filing
    • Total liabilities (annual): USD 13.57MSEC XBRL filing
    • Long-term debt (annual): USD 1.63MSEC XBRL filing
    • Cash & equivalents (annual): USD 881.49KSEC XBRL filing
    • Net margin (FY 2025-06-30): -30.3%Derived (calculated)
    • Gross margin (FY 2025-06-30): 17.8%Derived (calculated)
    • Operating income (YoY) (2025-06-30 vs 2024-06-30): -103.8%Derived (calculated)
    • R&D expense (YoY) (2025-06-30 vs 2024-06-30): 17.9%Derived (calculated)
    • Cost of revenue (YoY) (2025-06-30 vs 2024-06-30): 17.9%Derived (calculated)
    • EPS (diluted) (YoY) (2025-06-30 vs 2024-06-30): -73.5%Derived (calculated)
    • EPS (basic) (YoY) (2025-06-30 vs 2024-06-30): -73.5%Derived (calculated)
    • Revenue (YoY) (2025-06-30 vs 2024-06-30): -0.1%Derived (calculated)
    • Gross profit (YoY) (2025-06-30 vs 2024-06-30): -41.3%Derived (calculated)
    Showing 24 of 60 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-08-09EVENTUpcomingFY 2026 earnings (expected) estimated date
    2026-03-31 00:00 UTCINSIDER7 insider transactions — 2026-03 · net buy $236k 1 derivative
    2026-03-31INSIDERCOLL WAYNE M transacted 1.6k sh — Chief Financial Officer ~$6k
    2026-03-30FILINGFORM 8-K →
    2026-03-30INSIDERCOLL WAYNE M bought 20.8k sh — Chief Financial Officer ~$75k
    2026-03-30INSIDERTRAUT JOSEPH bought 41.7k sh — Chief Operating Officer ~$150k
    2026-03-30INSIDERForkey Joseph Norman bought 1.4k sh — Director, Chief Executive Officer ~$5k
    2026-03-20FILINGCURRENT REPORT →
    2026-03-12INSIDERMiclot Andrew J. transacted 20.0k sh — Director ~$29k
    2026-03-12INSIDERMiclot Andrew J. transacted 6.4k sh — Director ~$29k
    2026-03-12INSIDERMiclot Andrew J. disposed of 20.0k sh Employee Stock Option (right to buy) — Director
    2025-12-31 00:00 UTCINSIDER1 insider transaction — 2025-12 · net buy $8.9M
    2025-12-31INSIDERCOLL WAYNE M transacted 1.4k sh — Chief Financial Officer ~$8.88M
    2025-11-17 00:00 UTCINSIDER4 insider transactions — 2025-11 4 derivative
    2025-11-17INSIDERMiclot Andrew J. acquired 30.0k sh Stock Options (Rights to buy) — Director
    2025-11-17INSIDERDuncan Buell acquired 30.0k sh Stock Options (Rights to buy) — Director
    2025-11-17INSIDERWoodward Peter H acquired 30.0k sh Stock Options (Rights to buy) — Director
    2025-11-17INSIDERPellegrino Joseph P JR acquired 30.0k sh Stock Options (Rights to buy) — Director
    2025-10-03FILINGFORM 8-K →
    2025-10-01 00:00 UTCINSIDER1 insider transaction — 2025-10 1 derivative
    2025-10-01INSIDERTRAUT JOSEPH acquired 60.0k sh Stock Options (Rights to buy) — Chief Operating Officer
    2025-09-30 00:00 UTCINSIDER1 insider transaction — 2025-09 · net buy $8.6M
    2025-09-30INSIDERCOLL WAYNE M transacted 1.4k sh — Chief Financial Officer ~$8.56M
    2025-06-30 00:00 UTCINSIDER1 insider transaction — 2025-06 · net buy $8.8M
    2025-06-03FILINGCURRENT REPORT →
    2025-05-23FILINGCURRENT REPORT →
    2025-05-16 00:00 UTCINSIDER3 insider transactions — 2025-05 · $131k gross 1 derivative
    2025-03-31 00:00 UTCINSIDER11 insider transactions — 2025-03 · net buy $8.3M 9 derivative
    2007-11-20 15:01 UTCEARNINGSQuarterly results — Q3 2007 Revenue USD 6.7M · Net USD -1.6M
    2007-10-01 18:42 UTCEARNINGSQuarterly results — Q3 2007 Revenue USD 6.2M · Net USD -1.4M
    2007-10-01 18:42 UTCEARNINGSAnnual results — FY 2007 Revenue USD 19.1M · Net USD -5.8M
    2007-05-15 17:26 UTCEARNINGSQuarterly results — Q1 2007 Revenue USD 4.2M · Net USD -2.1M
    2007-02-15 16:52 UTCEARNINGSQuarterly results — Q4 2006 Revenue USD 4.5M · Net USD -1.0M
    Showing the 40 most recent of 47 entries.
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage